| Dr Jerome S Gans, MD | |
|
55 Cleveland Rd, Wellesley, MA 02481-2434 | |
| (781) 235-1546 | |
| (781) 239-0353 |
| Full Name | Dr Jerome S Gans |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 55 Cleveland Rd, Wellesley, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306837455 | NPI | - | NPPES |
| 2021706 | Medicaid | MA | |
| 709579 | Other | MA | TUFTS HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 31518 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jerome S Gans, MD Po Box 9142, Mass General Physician Organization, Charlestown, MA 02129-9142 Ph: (617) 724-0287 | Dr Jerome S Gans, MD 55 Cleveland Rd, Wellesley, MA 02481-2434 Ph: (781) 235-1546 |
News Archive
In the fall of 1917, a new strain of influenza swirled around the globe. At first, it resembled a typical flu epidemic: Most deaths occurred among the elderly, while younger people recovered quickly. However, in the summer of 1918, a deadlier version of the same virus began spreading, with disastrous consequence. In total, the pandemic killed at least 50 million people - about 3 percent of the world's population at the time.
The Netherlands' three Top Institutes for life-science research (the BioMedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma) today announced a joint investment of MEUR 28 on innovative research targeted at bringing personalized medicine closer to reality.
Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.
A new study in rats suggests that caffeine may offset some of the negative effects of an obesogenic diet by reducing the storage of lipids in fat cells and limiting weight gain and the production of triglycerides.
› Verified 1 days ago
Ekta Taneja, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 25 Walnut St Ste 300, Wellesley, MA 02481 Phone: 617-600-8823 | |
Nancy J Donovan, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 27 Mica Ln, Suite 106, Wellesley, MA 02481 Phone: 781-259-0050 | |
Doreen B. Kalter, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 372 Washington St, Wellesley, MA 02481 Phone: 781-239-3550 Fax: 781-239-3272 | |
Dr. Susan Edith Ruskin, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 11 River St, Wellesley, MA 02481 Phone: 781-647-0496 | |
Priyamvada Kota, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Harvard Vanguard Medical Associates, 230 Worcester Street, Wellesley, MA 02481 Phone: 781-431-5270 Fax: 781-431-5535 | |
Shih Yee-marie Tan Gipson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 18 Grove St # 6, Wellesley, MA 02482 Phone: 617-326-5102 | |
Alison C Phillips, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 27 Mica Ln, Suite 205, Wellesley, MA 02481 Phone: 781-237-2335 |